Thelansis

 Myelodysplastic syndrome (MDS) comprises a group of myeloid hematological disorders distinguished by reduced blood cell counts, abnormalities in the bone marrow, and a significant risk of evolving into acute myeloid leukemia (AML). Clinical manifestations primarily result from low blood cell counts, predominantly anemia, leading to fatigue, shortness of breath, and potentially angina. Less frequently, MDS may manifest as thrombocytopenia, resulting in spontaneous bleeding or neutropenia, making individuals susceptible to bacterial or, in rarer cases, fungal infections. The underlying cause remains unknown in 80% of cases. In the remaining 20%, it may be attributed to acquired factors such as prior chemotherapy or radiation therapy, occupational exposure to benzene derivatives or ionizing radiation, or inherited factors, including gene mutations mainly involving DDX41, GATA2, RUNX, and telomerase genes, or DNA instability (notably seen in Fanconi anemia patients who are prone to de...

Myelodysplastic syndromes (MDS) are a group of myeloid malignancies that result in dysplastic and ineffective hematopoiesis and have a poor 5-year relative survival estimate. The only curative treatment option for MDS is stem cell transplantation following high-dose chemotherapy and total body irradiation, which, given the toxicity of the treatment regimen, is typically reserved for younger, healthier patients. MDS in older patients or those without a suitable bone marrow donor is generally limited to supportive care with transfusions, hematopoietic growth factors, or chemotherapy. The incidence of MDS patients identified as eligible for 2nd -line therapy was 3/100,000. Approximately 9,500 people per year in the United States may be candidates for 2nd -line therapy for MDS. The risk of MDS increases with advancing age; approximately 86% of patients with newly diagnosed MDS in the United States are 60 years old (median age, 76 years). Thelansis’s “Myelodys...

The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production and a variable risk of transformation to acute leukemia.   Epidemiology- According to the literature review, the incidence of MDS in the US is about 4.1–4.6 cases per 100,000 population per year, with approximately 86% of patients aged ≥60years at the time of diagnosis (median age 76 years). The incidence rate is higher in men than women. The prevalence is slightly lower in Europe, with a reported 1.24–3.7 cases per 100,000 population per year.   The competitive landscape of Myelodysplastic syndromes (MDS) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Myelodysplastic syndromes (MDS) across 8 MM market from the center of Excellence/ Public/ Priv...